Padagis (formerly Perrigo) is a global pharmaceutical manufacturer that offers high quality generic Rx and OTC products that meet strict standards of quality and safety. The Padagis portfolio of dermatological products is the largest in the United States. Padagis has sub-licensed Evamist® for commercialisation in the US from Lumara Health, who licensed Evamist® from Acrux.
Gedeon Richter is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. With its widely acknowledged steroid chemistry expertise, Gedeon Richter is a significant player in the female healthcare field worldwide. Acrux has licensed manufacturing and marketing rights for its estradiol product (Lenzetto®) to Gedeon Richter for all territories excluding the United States, South Korea, Southern Africa, Switzerland and Australasia. Lenzetto® was launched in 2016 and is now sold in over 30 countries across the European Union and other markets including South America.
In January 2021 FDA approval was received for Testosterone Topical Solution, 30mg /1.5mL, a generic to Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. An exclusive sales, marketing and distribution agreement was signed with Dash Pharmaceuticals.
DASH is a privately held, specialty pharmaceutical company. The company markets, sells , and distributes generic pharmaceutical products, packaged in the “DASH” label. The DASH team continually evaluates and identifies generic product opportunities, across multiple dosage forms and therapeutic categories for sale in retail, institutional and other US pharmaceutical markets. Through partnerships with quality pharmaceutical developers and manufacturers around the world, the company co-develops and licenses products for its distribution.
For further information on Dash Pharmaceuticals LLC, visit www.dashpharm.com
In June 2020, Acrux Limited entered into an exclusive development and commercialisation agreement with Amring Pharmaceuticals, Inc. in the United States.
Amring Pharmaceuticals, Inc. is a privately held generic pharmaceutical company active in global markets geared to supplying unique and specialized products and is partnered with well-established global biopharmaceutical companies. Amring is uniquely positioned to leverage its partners’ expertise in bringing biotechnology derived medicines, as well as patient-friendly drug delivery systems, sterile manufacturing and other state-of-the-art technologies to the marketplace.
For further information on Amring, visit www.amringusa.com
In May 2020, Acrux DDS Pty Ltd has entered into an exclusive sales, marketing and distribution agreement with TruPharma, LLC (“TruPharma”) in the United States. Subject to approval by the US Food and Drug Administration, TruPharma will be responsible for the commercialisation of 6 existing products from the Acrux pipeline, including the sponsorship and management of each FDA application, management of commercial manufacturing, marketing and distribution of each product.
TruPharma (private) is a company focused on sales, marketing, and distribution of high-quality prescription pharmaceutical products in the U.S. market. TruPharma partners with skilled developers and reliable manufactures to bring niche and limited supply products to its customers. TruPharma is owned and operated by seasoned executives with extensive experience overcoming legal and regulatory hurdles to FDA approvals, and selling products to all classes of trade. TruPharma’s independence and experience has made it a front-end partner of choice for companies targeting the US pharmaceutical market.
For further information on TruPharma, visit www.trupharma.com